MT027

Asset

Allogeneic CAR-T cells target B7-H3-expressing cancer cells for destruction.

Stage: Phase 2
Modality: Cell therapy
Target: CD276; 2
Indications: 0
Trials: 1
Developer

Indications

2

Brain metastases from breast cancer
Phase 2, prnewswire.com, 12 Oct 2026
Brain metastases from lung cancer
Phase 2, prnewswire.com, 12 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.